This post was originally published on this site

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise. With the closing of Fund XII, Michael Gladstone was promoted to partner. Atlas Venture will continue to advance its mission of doing well by doingRead More »

The post Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership appeared first on Atlas Venture.